Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in
Alvotech has moved one step closer to entering the Eylea (aflibercept 2 mg) biosimilar market, after a European Medicines Agency …
Post
-
-
Harbour BioMed partners Otsuka on new T-cell therapy
Harbour BioMed has entered a strategic partnership with Otsuka Pharmaceutical focusing on the development of HBM7020, a B-cell maturation antigen …
-
Bridging the gap: A comprehensive approach to social determinants of health
As the focus on personalized, equitable healthcare continues to intensify, social determinants of health (SDoH) have attracted significant attention in …
-
EC approves argenx’s efgartigimod alfa for CIDP treatment
The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat …
-
From discovery to delivery: making therapies reach patients faster
The life science industry faces rapid innovation, technological advancement, growing complexity, and uncertainty. In this evolving landscape, convergence of AI, …
-
Madrigal poised to enter European MASH market after CHMP endorsement
Madrigal Pharmaceuticals has moved one step closer to marketing the first treatment for metabolic dysfunction-associated steatohepatitis (MASH) in Europe after …
-
London Biotechnology Show 2025: Novo Nordisk harnesses AI/ML to accelerate drug development landscape
Many biotechnology companies are navigating the various obstacles prevalent within the pharmaceutical industry with the implementation of artificial intelligence (AI) …
-
Podcast: The benefits of blockchain in healthcare
One of the key advantages of blockchain is that it removes the need for patients to provide the same information …
-
Novartis’ ribociclib approved in Canada for early breast cancer
Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the …
-
FDA cell and gene therapy director exit increases ‘volatility’ for sector
The departure of the US Food and Drug Administration’s (FDA) cell and gene therapy director and deputy director fuels ongoing …
-
NSW government invests $13.39m in life-changing therapies
The government of New South Wales (NSW), Australia, has announced an investment of A$20.7m ($13.39m) in access to life-changing therapies …
-
DoH – Abu Dhabi and Sanofi link for vaccine development
The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine …
-
CNS innovator oligonucleotide licensing value up 339% from £2bn in 2024
Innovator oligonucleotide-based drugs targeting central nervous system (CNS) indications witnessed a 339% ($2.17bn) increase in total licensing agreement deal value …
-
UK and US governments pursue contrasting vaccine strategies
While the outlook for vaccines in the US looks bleak under the current administration, the UK Government is pressing ahead …
-
Actio gains $66m to advance small molecule therapeutics pipeline
US-based Actio Biosciences has closed a Series B financing round, raising $66m to advance the genetics-driven small molecule therapeutics pipeline …
